Role of ADAM10 and ADAM17 in Regulating CD137 Function.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
08 Mar 2021
Historique:
received: 30 01 2021
revised: 01 03 2021
accepted: 05 03 2021
entrez: 3 4 2021
pubmed: 4 4 2021
medline: 23 4 2021
Statut: epublish

Résumé

Human CD137 (4-1BB), a member of the TNF receptor family, and its ligand CD137L (4-1BBL), are expressed on immune cells and tumor cells. CD137/CD137L interaction mediates bidirectional cellular responses of potential relevance in inflammatory diseases, autoimmunity and oncology. A soluble form of CD137 exists, elevated levels of which have been reported in patients with rheumatoid arthritis and various malignancies. Soluble CD137 (sCD137) is considered to represent a splice variant of CD137. In this report, however, evidence is presented that A Disintegrin and Metalloproteinase (ADAM)10 and potentially also ADAM17 are centrally involved in its generation. Release of sCD137 by transfected cell lines and primary T cells was uniformly inhibitable by ADAM10 inhibition. The shedding function of ADAM10 can be blocked through inhibition of its interaction with surface exposed phosphatidylserine (PS), and this effectively inhibited sCD137 generation. The phospholipid scramblase Anoctamin-6 (ANO6) traffics PS to the outer membrane and thus modifies ADAM10 function. Overexpression of ANO6 increased stimulated shedding, and hyperactive ANO6 led to maximal constitutive shedding of CD137. sCD137 was functionally active and augmented T cell proliferation. Our findings shed new light on the regulation of CD137/CD137L immune responses with potential impact on immunotherapeutic approaches targeting CD137.

Identifiants

pubmed: 33800462
pii: ijms22052730
doi: 10.3390/ijms22052730
pmc: PMC7962946
pii:
doi:

Substances chimiques

ANO6 protein, human 0
Anoctamins 0
Membrane Proteins 0
Neoplasm Proteins 0
Phospholipid Transfer Proteins 0
Tumor Necrosis Factor Receptor Superfamily, Member 9 0
Amyloid Precursor Protein Secretases EC 3.4.-
ADAM10 Protein EC 3.4.24.81
ADAM10 protein, human EC 3.4.24.81
ADAM17 Protein EC 3.4.24.86
ADAM17 protein, human EC 3.4.24.86

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : 125440785 (SFB877, project A4)
Organisme : Deutsche Forschungsgemeinschaft
ID : RTG1743

Références

Oncol Rep. 2006 May;15(5):1197-200
pubmed: 16596186
Cell. 2017 Dec 14;171(7):1638-1648.e7
pubmed: 29224781
J Immunol. 1998 Mar 1;160(5):2488-94
pubmed: 9498794
Blood. 2018 Jan 4;131(1):49-57
pubmed: 29118009
Oncoimmunology. 2015 Jun 24;5(1):e1062967
pubmed: 26942078
World J Gastroenterol. 2002 Dec;8(6):1129-33
pubmed: 12439939
Clin Chim Acta. 2010 Mar;411(5-6):406-10
pubmed: 20026323
Atherosclerosis. 2018 May;272:66-72
pubmed: 29571029
Clinics (Sao Paulo). 2013;68(2):193-8
pubmed: 23525315
Proc Natl Acad Sci U S A. 1989 Mar;86(6):1963-7
pubmed: 2784565
Comb Chem High Throughput Screen. 2005 Mar;8(2):161-71
pubmed: 15777180
Mol Biol Cell. 2009 Mar;20(6):1785-94
pubmed: 19158376
Nat Commun. 2016 May 10;7:11523
pubmed: 27161080
Leukemia. 2005 May;19(5):883-5
pubmed: 15744355
J Autoimmun. 2020 Aug;112:102499
pubmed: 32505443
J Leukoc Biol. 2007 Jul;82(1):173-6
pubmed: 17510296
Eur J Immunol. 1994 Feb;24(2):367-74
pubmed: 8299685
Gene. 1993 Dec 8;134(2):295-8
pubmed: 8262389
PLoS One. 2012;7(2):e31594
pubmed: 22389670
J Leukoc Biol. 2020 May;107(5):731-738
pubmed: 32052477
J Biol Chem. 2000 May 12;275(19):14608-14
pubmed: 10799547
Eur J Immunol. 2002 Dec;32(12):3617-27
pubmed: 12516549
J Biolumin Chemilumin. 1995 Jan-Feb;10(1):29-34
pubmed: 7762413
Antimicrob Agents Chemother. 2004 May;48(5):1593-9
pubmed: 15105110
J Immunol. 2015 Jan 1;194(1):134-41
pubmed: 25404362
Cancer Commun (Lond). 2019 Jul 9;39(1):41
pubmed: 31288851
Biochim Biophys Acta Mol Cell Res. 2018 Nov;1865(11 Pt A):1598-1610
pubmed: 30327201
Front Biosci (Landmark Ed). 2009 Jan 01;14:4173-88
pubmed: 19273343
J Immunol. 2010 Mar 1;184(5):2442-8
pubmed: 20118276
Arthritis Rheum. 2013 Jan;65(1):98-108
pubmed: 23124962
Life Sci Alliance. 2019 Aug 27;2(5):
pubmed: 31455669
Blood. 2003 Aug 15;102(4):1186-95
pubmed: 12714508
Eur J Immunol. 1994 Sep;24(9):2219-27
pubmed: 8088337
J Exp Med. 2018 Apr 2;215(4):1091-1100
pubmed: 29511066
Biochem J. 2000 Apr 1;347 Pt 1:131-8
pubmed: 10727411
Curr Top Microbiol Immunol. 2011;344:245-67
pubmed: 20582531
Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt B):2059-2070
pubmed: 28705384
J Immunol. 1993 Feb 1;150(3):771-81
pubmed: 7678621
Sci Rep. 2016 May 06;6:25550
pubmed: 27151651
Eur J Immunol. 1998 Jan;28(1):290-5
pubmed: 9485208
Mol Immunol. 2008 Sep;45(15):3990-9
pubmed: 18640726
Front Immunol. 2020 Mar 24;11:499
pubmed: 32265938
Blood. 1993 Dec 1;82(11):3430-6
pubmed: 8241510
J Immunol Methods. 1993 Mar 15;160(1):81-8
pubmed: 7680699
ESMO Open. 2020 Jul;4(Suppl 3):e000733
pubmed: 32611557
Science. 2008 Jan 11;319(5860):210-3
pubmed: 18187657
Clin Transl Sci. 2018 Jul;11(4):428-434
pubmed: 29697202
Eur J Immunol. 1993 Oct;23(10):2631-41
pubmed: 8405064
J Biol Chem. 2012 Jul 6;287(28):23678-89
pubmed: 22613720
J Leukoc Biol. 2011 Jan;89(1):21-9
pubmed: 20643812
J Immunol. 2013 Jun 15;190(12):6250-8
pubmed: 23677477
J Clin Invest. 2010 Aug;120(8):2731-44
pubmed: 20628198
Biochim Biophys Acta. 2004 Nov 17;1667(1):82-90
pubmed: 15533308
Sci Signal. 2015 Jan 27;8(361):ra11
pubmed: 25628461
Exp Mol Med. 2004 Feb 29;36(1):13-22
pubmed: 15031666
Cell Rep. 2020 Mar 24;30(12):4124-4136.e5
pubmed: 32209473
Front Immunol. 2020 Dec 10;11:553715
pubmed: 33362756
Eur J Neurosci. 2000 Sep;12(9):3443-7
pubmed: 10998128
Transl Res. 2015 Sep;166(3):244-53
pubmed: 25796462
Semin Immunol. 1998 Dec;10(6):491-9
pubmed: 9826582
Oncoimmunology. 2019 Sep 6;8(12):e1651622
pubmed: 31741755
J Biol Chem. 2013 Nov 29;288(48):34529-44
pubmed: 24121505
Cancer Immunol Res. 2019 Oct;7(10):1564-1569
pubmed: 31575551
J Immunol Methods. 1984 Aug 3;72(1):127-32
pubmed: 6431008
Croat Med J. 2008 Apr;49(2):192-200
pubmed: 18461674
Int J Obes (Lond). 2014 Aug;38(8):1075-82
pubmed: 24281650
Mol Biol Cell. 2007 Jan;18(1):176-88
pubmed: 17079736
J Mol Cell Biol. 2019 Dec 23;11(11):979-993
pubmed: 30753537

Auteurs

Jana Seidel (J)

Department of Dermatology, University of Kiel, 24105 Kiel, Germany.

Sinje Leitzke (S)

Department of Dermatology, University of Kiel, 24105 Kiel, Germany.

Björn Ahrens (B)

Department of Dermatology, University of Kiel, 24105 Kiel, Germany.

Maria Sperrhacke (M)

Department of Dermatology, University of Kiel, 24105 Kiel, Germany.

Sucharit Bhakdi (S)

Independent Researcher, 24105 Kiel, Germany.

Karina Reiss (K)

Department of Dermatology, University of Kiel, 24105 Kiel, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH